Full Name
Qiang Yu
Variants
Yu, Qiang
Yu, Q.
 
Main Affiliation
 
 
Email
phsyq@nus.edu.sg
 

Publications

Results 1-10 of 10 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
12009BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin APuppe, J; Drost, R; Liu, X; Joosse, S.A; Evers, B; Cornelissen-Steijger, P; Nederlof, P; Yu, Q ; Jonkers, J; van Lohuizen, M; Pietersen, A.M
22009Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cellsSun, F. ; Wu, Z.; Yang, X.; Yu, Q. ; Chan, E.; Marquez, V.E.
32015Erratum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel (Nature Communications (2015) 6 (8746) DOI: 10.1038/ncomms9746)Wee, Z.N.; Yatim, S.M.J.M.; Kohlabauer, V.K.; Feng, M.; Goh, J.Y.; Bao, Y.; Lee, P.L.; Zhang, S. ; Wang, P.P.; Lim, E.; Tam, W.L. ; Cai, Y.; Ditzel, H.J.; Hoon, D.S.B.; Tan, E.Y.; Yu, Q. 
42015Functional characterization of D9, a novel deazaneplanocin a (DZNep) analog, in targeting acute myeloid leukemia (AML)Jiang, Xia; Lim, Cheryl Zi Hui; Li, Zhimei; Lee, Puayleng; Yatim, Siti Maryam J. M.; Guan, Peiyong; Li, Juntao; Zhou, Jianbiao ; Pan, Jingxuan; Chng, Wee Joo ; Chai, Li Lin Christina ; Yu, Qiang 
52015IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelWee, Z.N; Yatim, S.M.J.M; Kohlbauer, V.K; Feng, M; Goh, J.Y; Yi, B; Lee, P.L; Zhang, S ; Wang, P.P; Lim, E; Tam, W.L ; Cai, Y; Ditzel, H.J; Hoon, D.S.B; Tan, E.Y; Yu, Q 
62010Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expressionWu, Z.L.; Zheng, S.S.; Li, Z.M.; Qiao, Y.Y.; Aau, M.Y.; Yu, Q. 
72008Saturated fatty acids modulate cell response to DNA damage: Implication for their role in tumorigenesisZeng L. ; Wu G.-Z.; Goh K.J.; Lee Y.M. ; Ng C.C.; You A.B.; Wang J.; Jia D.; Hao A.; Yu Q. ; Li B.
821-Jul-2021Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal CancerWang, Wenyu; Tang, Yen-An; Xiao, Qian; Lee, Wee Chyan; Cheng, Bing; Niu, Zhitong; Oguz, Gokce; Feng, Min; Lee, Puay Leng; Li, Baojie; Yang, Zi-huan; Chen, Yu-feng; Lan, Ping; Wu, Xiao-Jian; Yu, Qiang 
92014The KDM2B-let-7b-EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapyKaroopongse E.; Yeung C.; Byon J.; Ramakrishnan A.; Holman Z.J.; Jiang P.Y.Z.; Yu Q. ; Deeg H.J.; Marcondes A.M.
102017VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinomaYao, X; Tan, J; Lim, K.J ; Koh, J; Ooi, W.F; Li, Z; Huang, D; Xing, M; Chan, Y.S; Qu, J.Z; Tay, S.T ; Wijaya, G; Lam, Y.N; Hong, J.H ; Lee-Lim, A.P; Guan, P; Ng, M.S.W; He, C.Z; Lin, J.S; Nandi, T; Qamra, A ; Xu, C ; Myint, S.S; Davies, J.O.J; Goh, J.Y; Loh, G; Tan, B.C; Rozen, S.G ; Yu, Q ; Tan, I.B.H ; Cheng, C.W.S ; Li, S ; Chang, K.T.E ; Tan, P.H; Silver, D.L ; Lezhava, A; Steger, G; Hughes, J.R; Teh, B.T ; Tan, P